Sunshine Coast University Private Hospital has joined a pioneering clinical trial investigating a potential new oral therapy for psoriatic arthritis, offering fresh hope for people living with the painful and often debilitating condition.
Psoriatic arthritis causes inflammation of the joints, leading them to become painful, stiff and often swollen. Currently there is no cure for psoriatic arthritis.
The trials Principal Investigator, Dr Sue Thackwray, said the study has the potential to address a significant unmet need.
“Psoriatic arthritis can have a huge impact on people’s lives, affecting mobility, energy and mental wellbeing. While there are existing therapies, many are injectable or infusion-based and remission rates remain low,” Dr Thackwray said.
“This trial is investigating an oral therapy that acts at a very specific level of the inflammatory pathway. We hope this targeted approach could provide better control of symptoms with fewer side effects, while also being more convenient for patients.”
Dr Thackwray said clinical trials play a vital role in expanding treatment options for people living with chronic autoimmune conditions.
“We are proud to be part of this global study, and we encourage eligible patients on the Sunshine Coast and beyond to consider taking part,” she said.
Adults diagnosed with psoriatic arthritis who are interested in participating are invited to express their interest online: www.sunshinecoastuniversityprivate.com.au/Our-Services/Clinical-Trials
The study is being run at Sunshine Coast University Private Hospital as part of the Ramsay Clinical Trials Network.
